Linklaters has advised Amplex AB on its public cash offer for ADDvice Group AB (publ)

Linklaters advised Amplex AB on a public cash offer — and the financing for that offer — covering all four listed instruments of ADDvise Group AB (publ), valuing the Stockholm‑listed life‑sciences group at more than SEK 1 billion. ADDvise, which comprises over 20 companies across Lab and Healthcare, reports annual revenues close to SEK 1.7 billion, making the deal a notable consolidation move in the Nordic life‑science services sector. The Linklaters team advising on the transaction was led by partners Magnus Wennerhorn and Charlotte Levin.

Analysis

Linklaters advised Amplex AB on a public cash offer for ADDvise Group AB (publ) and on financing for that offer; the takeover covers all four listed instruments and values ADDvise at more than SEK 1 billion. ADDvise is described as an international life-science group spanning more than 20 companies across Lab and Healthcare and reporting annual revenues close to SEK 1.7 billion, establishing it as a non-trivial regional consolidator.

The disclosed valuation implies an enterprise-value-to-revenue ratio of roughly 0.59x (SEK 1.0bn / SEK 1.7bn), which is low relative to high-growth biotech multiples and more in line with service/asset-aggregation businesses; this speaks to either conservative pricing by the bidder or material liabilities/earnings risk not disclosed in the release. Linklaters’ role on financing indicates external funding or structured capital is involved, which raises execution and leverage considerations for the transaction.

Market signals attach a mildly positive sentiment and limited market-impact (score ~0.25), but key near-term catalysts remain the detailed offer terms, financing structure disclosures and regulatory or shareholder approvals; integration of 20+ subsidiaries and treatment of minority holders will determine value realization for bidders and sellers.

Key Decisions for Investors

• Monitor the formal offer document and financing disclosures closely for deal price, premiums, covenants and conditionality before taking a position in ADDvise or Amplex-related instruments
• Revalue exposure to Nordic life-science services names using the implied ~0.59x revenue benchmark to identify potential undervaluation or contagion risk among peers
• Avoid directional commitments until shareholder approval and financing completion are clear; consider hedging or size limits to protect against transaction or integration failure
• Watch for further consolidation opportunities in the sector as this transaction could catalyze strategic M&A, and selectively accumulate high-quality service providers if financing markets remain supportive